Komori
Treasury shares4534Mochida Pharmaceutical Co.,Ltd.Pharmaceuticals

Notice Regarding the Status of Share Repurchases

During the one-month period of August 2026, the Company acquired 82,000 treasury shares through market purchases for approximately ¥264.71 million. Cumulative acquisitions based on the Board of Directors’ resolution totaled 268,500 shares, for approximately ¥868.28 million.

Worth reading
49Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Neutral
Direction inferred from the company’s description.
Scale
264719000
yen
Wording
Definitive
How definitive the wording is.

Progress against acquisition limit

Market purchases on the Tokyo Stock Exchange

Resolved 30 March 2026 / Acquisition period 18 May 2026 to 18 December 2026

50.7%
Cumulative utilization rate
Limit261,500 株 remaining
Number of Shares530,000 shares (maximum)
43.4%
Cumulative utilization rate
LimitShares 50.7%1,131,716,000 円 remaining
Amount¥2,000,000,000 (maximum)

The darker band is the portion acquired this time (1 August 2026 to 31 August 2026 (on an execution-date basis)). At this pace, the share-count limit will be reached first, and the acquisition will end without using the full monetary limit.

Number of Shares
Limit530,000 shares (maximum)
Cumulative total268,500 shares (as of 31 August 2026)
Current82,000 shares
Amount
Limit¥2,000,000,000 (maximum)
Cumulative total¥868,284,000 (as of 31 August 2026)
Current¥264,719,000
Percentage of total issued shares1.50% (percentage of issued shares excluding treasury shares)
Average acquisition price for this transaction (calculated)¥3,228 per shareCurrent acquisition price ÷ current number of shares acquired

消化率と残りは、会社が示した累計・今回と上限から算出しています。進捗率=上限に対してどこまで使ったかの割合です。

Progress against acquisition limit
ItemDetails
Total number of shares acquired in this transaction82,000 shares
Total current acquisition price¥264,719,000
Acquisition date/acquisition period1 August 2026 to 31 August 2026 (on an execution-date basis)
Method of acquisitionMarket purchases on the Tokyo Stock Exchange
Cumulative number of shares acquired268,500 shares (as of 31 August 2026)
Cumulative acquisition cost¥868,284,000 (as of 31 August 2026)
Resolution date30 March 2026
Maximum number of shares to be acquired530,000 shares (maximum)
Total acquisition price¥2,000,000,000 (maximum)
Acquisition period under the resolution18 May 2026 to 18 December 2026
Percentage of total issued shares1.50% (percentage of issued shares excluding treasury shares)
Items this document does not state (2)
Whether acquisition has been completedAverage Acquisition Price

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

To report the status of the acquisition of treasury shares pursuant to Article 156 of the Companies Act, as applied by replacing certain terms pursuant to Article 165, Paragraph 3 of the same Act. The resolution also states that some or all of the shares may not be acquired depending on market conditions.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Notice Regarding the Status of Share Repurchases | Mochida Pharmaceutical Co.,Ltd. (4534) timely disclosure | Komori